Nuvo International Group Inc, a leader in remote pregnancy monitoring and AI-driven maternal-fetal care, has unveiled a new pregnancy data solution created from real-world use of its FDA-cleared INVU pregnancy monitoring wearable technology. The device has enabled Nuvo to gather what it believes is the largest longitudinal dataset of synchronized maternal and fetal physiological signals recorded during pregnancy. This dataset includes more than 350,000 minutes of monitoring collected over 25,000 sessions from both clinical and home environments, reflecting real-world conditions and usage over several years.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
Laurence Klein, Chief Executive Officer of Nuvo International Group Inc, explained that the INVU wearable has made it possible to build a comprehensive, multimodal dataset based on actual patient experiences. He emphasized that this approach creates a foundation for AI-driven insights into pregnancy that has not existed before and allows healthcare providers and researchers to measure and understand the health of both mother and child in ways that are more continuous and precise.
Unlike traditional pregnancy monitoring, which often relies on short clinic visits or a single type of measurement, Nuvo’s solution captures multiple physiological signals from the mother and fetus simultaneously. These signals include fetal electrocardiography, fetal phonocardiography, maternal electrocardiography, maternal phonocardiography, motion data, and structured pregnancy information. ECG measures the electrical activity of the heart while phonocardiography records its acoustic signals. By collecting these signals together over time, the device allows both electrical and mechanical aspects of the maternal and fetal heart to be analyzed simultaneously, providing a more complete and accurate view of health.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
The INVU system combines electrical and mechanical heart signals, enabling cross-validation of measurements and improving signal quality while reducing noise from movement. This multimodal approach delivers greater clarity than single-signal or ultrasound-based systems. Because the data is collected continuously rather than in isolated sessions, it provides the opportunity to track changes in maternal and fetal physiology over time, making it ideal for AI applications that detect trends and patterns across large populations.
The development of Nuvo’s data solution is the result of years of regulated clinical use and the integration of the INVU wearable, software, and cloud-based infrastructure. This combined system positions INVU as more than a monitoring device; it is an insights platform designed to support continuous, personalized, and data-driven pregnancy care.
INVU also supports FDA-cleared, AI-powered Non-Stress Tests that incorporate fetal and maternal heart rates and uterine activity. Nuvo anticipates that the synchronized data streams will enable new clinical insights, including early indicators of fetal distress, changes in maternal cardiovascular function, and other pregnancy-specific risk patterns that are difficult to detect with conventional approaches.
To advance research and discovery in maternal-fetal health, Nuvo has received approval from an independent Institutional Review Board to conduct retrospective analyses of de-identified pregnancy monitoring data. This approval allows Nuvo and research partners to study previously collected data responsibly and ethically, further improving understanding of maternal and fetal health while maintaining strict privacy and patient protections.
Nuvo’s platform reflects years of careful clinical use, patient consent, and integration of wearable technology, software, and cloud systems. By combining these elements, the INVU solution provides a foundation for the future of pregnancy care that is continuous, personalized, and powered by real-world data and AI insights.
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
